Puma Biotechnology Return On Asset vs. Price To Sales
| PBYI Stock | USD 6.27 -0.06 -0.95% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.86 | 0.7453 |
|
|
The profitability profile for Puma Biotechnology reflects how income compares to revenue, assets, and capital. All values are derived from reported financial statements.
Puma Biotechnology's Segment Revenue Breakdown
Puma Biotechnology's top line is composed of 2 product-level revenue streams. At 59.88 Million, Product is Puma Biotechnology's largest segment (79.4%), with Royalty as the second-largest at 15.57 Million. With the top segment exceeding 60% of revenue, Puma Biotechnology's earnings are heavily concentrated in a single product line.
Your Equity Center.
Macro event markers
Revenue Breakdown by Earning Segment for Puma Biotechnology Details
The breakdown below shows how Puma Biotechnology's revenue is split across product segments for the most recent reporting period. On the smaller end, Royalty contributes 20.6% to Puma Biotechnology's revenue.
Forward-looking earnings context helps frame Puma Biotechnology performance expectations. This view summarizes available data without implying outcomes.
Quarterly Earnings Growth -0.34 | Earnings Share 0.62 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. This view summarizes available data without implying outcomes.
The concept of value for Puma Biotechnology differs from its quoted price, since each reflects a different lens. This information is provided for contextual purposes.
Puma Biotechnology Price To Sales vs. Return On Asset Fundamental Analysis
Sector-based pricing multiples position Puma Biotechnology within its competitive valuation range. Puma Biotechnology claims the number one ranking for return on asset among direct rivals. It is rated below average for price to sales among direct rivals recording roughly 13.00 in Price To Sales for every unit of Return On Asset. Year-over-year analysis suggests Price To Sales Ratio is positioned to increase noticeably. A year ago, Puma Biotechnology reported Price To Sales Ratio at 1.30. Valuation multiples such as P/E, P/B, and P/S compare Puma Biotechnology to peer earnings performance.Puma Price To Sales vs. Return On Asset
Return on Assets (ROA) measures how efficiently a company generates profit relative to its total asset base. It is calculated by dividing net income by total assets and reflects management's effectiveness at deploying capital across the business. ROA is particularly useful for comparing companies within the same industry, since asset intensity varies widely across sectors.
Puma Biotechnology |
| = | 0.11 |
A higher ROA indicates that each dollar of assets produces more income, which generally signals operational efficiency. Asset-heavy industries such as banking, utilities, and manufacturing tend to have lower ROAs than asset-light businesses like software or professional services. When ROA is low, it may indicate either underperforming operations or a capital-intensive business model that requires ongoing investment to sustain revenue.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Puma Biotechnology |
| = | 1.41 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much the market values every dollar of the company's sales.
Puma Price To Sales Comparison
Puma Biotechnology is currently under evaluation for price to sales among direct rivals.
Puma Biotechnology Profitability Projections
Without lasting profits, Puma Biotechnology would in time produce negative long-term returns for its investors. The rate of change in Puma Biotechnology's profit metrics often matters more than the level itself. Puma Biotechnology currently maintains a profit margin of 13.6%.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | 36 K | 37.8 K | |
| Operating Income | 37.3 M | 39.2 M | |
| Income Before Tax | 35.8 M | 37.6 M | |
| Net Income | 31.1 M | 32.7 M | |
| Net Income From Continuing Ops | 31.1 M | 32.7 M | |
| Non Operating Income Net Other | -10.5 M | -10 M | |
| Total Other Income Expense Net | -1.5 M | -1.6 M | |
| Net Income Applicable To Common Shares | 2.3 K | 2.4 K | |
| Income Tax Expense | 4.7 M | 4.9 M | |
| Net Interest Income | -2.5 M | -2.7 M | |
| Interest Income | 4.1 M | 2.1 M | |
| Change To Netincome | 21.7 M | 20.6 M | |
| Net Income Per Share | 0.62 | 0.65 | |
| Income Quality | 1.34 | 1.41 | |
| Net Income Per E B T | 0.87 | 0.70 |
Puma Profitability Driver Comparison
Profitability drivers are factors that directly affect the investment outlook for Puma Biotechnology. Investors holding Puma Biotechnology's stock face unpredictable events that can materially affect the company's earnings.
Earnings Estimation Breakdown
The calculation of Puma Biotechnology's earnings per share is based on data from the past 12 consecutive months used for reporting the company's financial figures. The next projected EPS of Puma Biotechnology is estimated to be 0.07 with the future projection ranging from a low of 0.07 to a high of 0.07. Please be aware that this consensus of annual earnings estimates for Puma Biotechnology is based on EPS before non-recurring items.Last Reported EPS
0.07 Lowest | Expected EPS | 0.07 Highest |
Earnings Projection Consensus
A consensus EPS-based estimate above Puma Biotechnology's current price may suggest the market is pricing in excessive pessimism or overlooking near-term catalysts. Conversely, an estimate below market price could reflect a premium valuation that requires sustained earnings growth to justify. Both interpretations demand risk assessment and should not be acted upon in isolation.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 1 | 45.4% | 0.0 | 0.07 | 0.62 |
Earnings per Share Projection vs Actual
When Puma Biotechnology reports actual EPS, investors compare it against the analyst consensus estimate for Puma Biotechnology to judge performance. A beat versus consensus is typically interpreted as positive execution; a miss signals a shortfall relative to expectations. EPS is expressed on a weighted average per-share basis to account for equity changes within the reporting period.Estimated Months Earnings per Share
EPS serves income investors in Puma Biotechnology as a quick gauge of dividend affordability: the higher the EPS relative to the dividend per share, the more cushion management has. However, accounting EPS can diverge from cash-based earnings, so investors should validate EPS signals with operating cash flow and capex data. Comparing Puma Biotechnology's EPS to sector peers provides further context for dividend sustainability.Quarterly Analyst Estimates and Surprise Metrics
Earnings surprise history for Puma Biotechnology's reveals whether the company tends to guide conservatively or struggles to meet analyst expectations. A pattern of consistent beats signals strong management execution; repeated misses may indicate structural challenges. Analyst EPS estimates are formed from a combination of forward guidance, sector trends, and macroeconomic inputs.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-26 | 2025-12-31 | 0.27 | 0.29 | 0.02 | 7 | ||
2025-11-06 | 2025-09-30 | 0.16 | 0.21 | 0.05 | 31 | ||
2025-08-07 | 2025-06-30 | 0.09 | 0.12 | 0.03 | 33 | ||
2025-04-30 | 2025-03-31 | -0.22 | 0.1 | 0.32 | 145 | ||
2025-02-26 | 2024-12-31 | 0.14 | 0.43 | 0.29 | 207 | ||
2024-11-07 | 2024-09-30 | 0.35 | 0.41 | 0.06 | 17 | ||
2024-08-01 | 2024-06-30 | -0.13 | -0.09 | 0.04 | 30 | ||
2024-05-02 | 2024-03-31 | -0.22 | -0.1 | 0.12 | 54 | ||
2024-02-29 | 2023-12-31 | 0.3 | 0.26 | -0.04 | 13 | ||
2023-11-02 | 2023-09-30 | 0.08 | 0.12 | 0.04 | 50 | ||
2023-08-03 | 2023-06-30 | 0.01 | 0.05 | 0.04 | 400 | ||
2023-05-04 | 2023-03-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2023-03-02 | 2022-12-31 | 0.01 | -0.12 | -0.13 | 1300 | ||
2022-11-03 | 2022-09-30 | -0.05 | -0.01 | 0.04 | 80 | ||
2022-08-04 | 2022-06-30 | 0.0102 | 0.21 | 0.1998 | 1958 | ||
2022-05-05 | 2022-03-31 | -0.17 | -0.08 | 0.09 | 52 | ||
2022-03-03 | 2021-12-31 | -0.09 | 0.1 | 0.19 | 211 | ||
2021-11-04 | 2021-09-30 | -0.31 | -0.9 | -0.59 | 190 | ||
2021-08-05 | 2021-06-30 | -0.27 | -0.13 | 0.14 | 51 | ||
2021-05-06 | 2021-03-31 | 0.09 | 0.4 | 0.31 | 344 | ||
2021-02-25 | 2020-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2020-11-05 | 2020-09-30 | -0.39 | -0.79 | -0.4 | 102 | ||
2020-08-06 | 2020-06-30 | -0.3 | 0.08 | 0.38 | 126 | ||
2020-05-07 | 2020-03-31 | -0.77 | -0.43 | 0.34 | 44 | ||
2020-02-20 | 2019-12-31 | -0.48 | -0.29 | 0.19 | 39 | ||
2019-11-06 | 2019-09-30 | -0.71 | -0.44 | 0.27 | 38 | ||
2019-08-08 | 2019-06-30 | -0.95 | -0.97 | -0.02 | 2 | ||
2019-05-09 | 2019-03-31 | -0.68 | -0.26 | 0.42 | 61 | ||
2019-02-28 | 2018-12-31 | -0.77 | -0.8 | -0.03 | 3 | ||
2018-11-01 | 2018-09-30 | -0.97 | -0.37 | 0.6 | 61 | ||
2018-08-09 | 2018-06-30 | -1.26 | -1.17 | 0.09 | 7 | ||
2018-05-09 | 2018-03-31 | -1 | -0.65 | 0.35 | 35 | ||
2018-03-01 | 2017-12-31 | -1.97 | -1.71 | 0.26 | 13 | ||
2017-11-09 | 2017-09-30 | -2.58 | -2.07 | 0.51 | 19 | ||
2017-08-09 | 2017-06-30 | -2.04 | -2.1 | -0.06 | 2 | ||
2017-05-10 | 2017-03-31 | -1.98 | -1.97 | 0.01 | 0 | ||
2017-03-01 | 2016-12-31 | -1.92 | -2.04 | -0.12 | 6 | ||
2016-11-09 | 2016-09-30 | -1.96 | -2.02 | -0.06 | 3 | ||
2016-08-09 | 2016-06-30 | -2.18 | -2.05 | 0.13 | 5 | ||
2016-05-10 | 2016-03-31 | -1.99 | -2.19 | -0.2 | 10 | ||
2016-02-29 | 2015-12-31 | -1.95 | -1.9 | 0.05 | 2 | ||
2015-11-09 | 2015-09-30 | -1.84 | -1.87 | -0.03 | 1 | ||
2015-08-10 | 2015-06-30 | -1.55 | -2.01 | -0.46 | 29 | ||
2015-05-11 | 2015-03-31 | -1.35 | -1.66 | -0.31 | 22 | ||
2015-03-02 | 2014-12-31 | -1.19 | -1.57 | -0.38 | 31 | ||
2014-11-10 | 2014-09-30 | -1.21 | -1.19 | 0.02 | 1 | ||
2014-08-11 | 2014-06-30 | -0.66 | -1.29 | -0.63 | 95 | ||
2014-05-12 | 2014-03-31 | -0.48 | -0.67 | -0.19 | 39 | ||
2014-03-03 | 2013-12-31 | -0.49 | -0.56 | -0.07 | 14 | ||
2013-11-12 | 2013-09-30 | -0.46 | -0.5 | -0.04 | 8 | ||
2013-08-06 | 2013-06-30 | -0.43 | -0.44 | -0.01 | 2 | ||
2013-05-09 | 2013-03-31 | -0.63 | -0.41 | 0.22 | 34 | ||
2013-03-31 | 2012-12-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2012-11-14 | 2012-09-30 | -0.52 | -1.29 | -0.77 | 148 | ||
2012-08-14 | 2012-06-30 | -0.35 | -0.22 | 0.13 | 37 | ||
2012-05-15 | 2012-03-31 | -0.25 | -0.57 | -0.32 | 128 |
Use Puma Biotechnology in pair-trading
Pair analysis around Puma Biotechnology matters because it can turn one security idea into a more market-neutral structure. The advantage is that adverse movement in one leg may be partly offset by the other when correlation and thesis alignment hold.
Puma Biotechnology Pair Trading
Puma Biotechnology Pair Trading Analysis
Finding closely correlated positions to Puma Biotechnology provides context for tax-loss harvesting analysis. Selling Puma Biotechnology at a loss and repurchasing it immediately would violate IRS wash-sale rules.
The correlation of Puma Biotechnology is a statistical measure of how it moves in relation to other instruments. Values near +1 indicate near-identical movement to Puma Biotechnology, while values near -1 suggest inverse movement.
Pair evaluation and Correlation analysis for Puma Biotechnology provide hedging context. The context can be applied within sectors, industries, or broader universes.Use Investing Themes to Complement your Puma Biotechnology position
At 322.05 Million in the Biotechnology space, Puma Biotechnology smaller-cap profile gives investors a structured starting point for building sector-aligned themes. For Puma Biotechnology in Biotechnology, the theme workflow defines the investment thesis first, then optimizes which Healthcare assets best express that view at the smaller-cap level.
Did You Try This Idea?
Run Software Thematic Idea Now
Software
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 47 constituents at this time.
Explore the Software Theme as a thematic allocation that can be optimized for return targets or risk constraints.
| View All Next | Launch |